GB202117015D0 - New pharmaceutical composition - Google Patents
New pharmaceutical compositionInfo
- Publication number
- GB202117015D0 GB202117015D0 GBGB2117015.4A GB202117015A GB202117015D0 GB 202117015 D0 GB202117015 D0 GB 202117015D0 GB 202117015 A GB202117015 A GB 202117015A GB 202117015 D0 GB202117015 D0 GB 202117015D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- new pharmaceutical
- new
- composition
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2117015.4A GB202117015D0 (en) | 2021-11-25 | 2021-11-25 | New pharmaceutical composition |
ARP220103244A AR127780A1 (en) | 2021-11-25 | 2022-11-25 | NEW PHARMACEUTICAL COMPOSITION THAT COMPRISES ADRENALINE |
CA3238850A CA3238850A1 (en) | 2021-11-25 | 2022-11-25 | Pharmaceutical composition comprising adrenaline |
TW111145222A TW202333658A (en) | 2021-11-25 | 2022-11-25 | New pharmaceutical composition comprising adrenaline |
AU2022395920A AU2022395920A1 (en) | 2021-11-25 | 2022-11-25 | Pharmaceutical composition comprising adrenaline |
EP22814495.2A EP4236921A1 (en) | 2021-11-25 | 2022-11-25 | Pharmaceutical composition comprising adrenaline |
PCT/GB2022/052996 WO2023094826A1 (en) | 2021-11-25 | 2022-11-25 | Pharmaceutical composition comprising adrenaline |
US18/323,101 US11957647B2 (en) | 2021-11-25 | 2023-05-24 | Pharmaceutical composition comprising adrenaline |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2117015.4A GB202117015D0 (en) | 2021-11-25 | 2021-11-25 | New pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202117015D0 true GB202117015D0 (en) | 2022-01-12 |
Family
ID=79602314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2117015.4A Ceased GB202117015D0 (en) | 2021-11-25 | 2021-11-25 | New pharmaceutical composition |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB202117015D0 (en) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5702362A (en) | 1995-05-26 | 1997-12-30 | Bayer Aktiengesellschaft | Nasal applicator |
US6398074B1 (en) | 1998-03-10 | 2002-06-04 | Valois S.A. | Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir |
US20050001411A1 (en) | 2001-09-06 | 2005-01-06 | Christian Theiss | Method for the determination of parameters of a seat passenger |
US6938798B2 (en) | 2000-12-08 | 2005-09-06 | Tebro S.A. | Fluid or powdery product dispensing device |
US7722566B2 (en) | 2003-10-09 | 2010-05-25 | Shin Nippon Biomedical Laboratories, Ltd. | Device to deliver a powdery medicine into nasal cavity |
WO2010142696A1 (en) | 2009-06-11 | 2010-12-16 | Charité - Universitätsmedizin Berlin | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
US20110045088A1 (en) | 2009-07-31 | 2011-02-24 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
US7947742B2 (en) | 2002-06-28 | 2011-05-24 | Civitas Therapeutics, Inc. | Inhalable epinephrine |
WO2014004400A2 (en) | 2012-06-28 | 2014-01-03 | The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services | Nasal dry powder delivery system for vaccines and other treatment agents |
US9724713B2 (en) | 2013-07-05 | 2017-08-08 | Aptar France Sas | Fluid or powdery product dispensing device |
US20180092839A1 (en) | 2016-10-03 | 2018-04-05 | Lance L. Gooberman | Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders |
WO2019038756A1 (en) | 2017-08-20 | 2019-02-28 | Solubest Ltd. | Dry powder compositions for intranasal delivery |
US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
-
2021
- 2021-11-25 GB GBGB2117015.4A patent/GB202117015D0/en not_active Ceased
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5702362A (en) | 1995-05-26 | 1997-12-30 | Bayer Aktiengesellschaft | Nasal applicator |
US6398074B1 (en) | 1998-03-10 | 2002-06-04 | Valois S.A. | Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir |
US6938798B2 (en) | 2000-12-08 | 2005-09-06 | Tebro S.A. | Fluid or powdery product dispensing device |
US20050001411A1 (en) | 2001-09-06 | 2005-01-06 | Christian Theiss | Method for the determination of parameters of a seat passenger |
US8747813B2 (en) | 2002-06-28 | 2014-06-10 | Civitas Therapeutics, Inc. | Inhalable epinephrine |
US7947742B2 (en) | 2002-06-28 | 2011-05-24 | Civitas Therapeutics, Inc. | Inhalable epinephrine |
US8415397B2 (en) | 2002-06-28 | 2013-04-09 | Civitas Therapeutics, Inc. | Inhalable epinephrine |
US7722566B2 (en) | 2003-10-09 | 2010-05-25 | Shin Nippon Biomedical Laboratories, Ltd. | Device to deliver a powdery medicine into nasal cavity |
WO2010142696A1 (en) | 2009-06-11 | 2010-12-16 | Charité - Universitätsmedizin Berlin | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
US20110045088A1 (en) | 2009-07-31 | 2011-02-24 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
WO2014004400A2 (en) | 2012-06-28 | 2014-01-03 | The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services | Nasal dry powder delivery system for vaccines and other treatment agents |
US9724713B2 (en) | 2013-07-05 | 2017-08-08 | Aptar France Sas | Fluid or powdery product dispensing device |
US20180092839A1 (en) | 2016-10-03 | 2018-04-05 | Lance L. Gooberman | Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders |
WO2019038756A1 (en) | 2017-08-20 | 2019-02-28 | Solubest Ltd. | Dry powder compositions for intranasal delivery |
US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
Non-Patent Citations (14)
Title |
---|
"Auiton's Pharmaceutics: The Design and Manufacture of Medicines", 2017, ELSEVIER |
"Pharmaceutical Dosage Forms: Tablets", vol. 1, 2008, CRC PRESS |
"Remington: The Science and Practice of Pharmacy", 2020, PHARMACEUTICAL PRESS |
"The HLB System: A Time-Saving Guide to Emulsifier Selection", 1976, ICI AMERICAS INC, pages: 20 - 21 |
BERTAN ET AL., EUR. J. PHARM. SCI., vol. 27, 2006, pages 62 |
GANDHI, ADVANCED DRUG DELIVERY REVIEWS, vol. 43, 1994, pages 67 |
J. DRUG DELIVERY, vol. 5635010, 2018, pages 1 - 19 |
KOUZHOU ET AL.: "Amorphous Solid Dispersions", 2014, SPRINGER |
LACHMAN: "The Theory and Practice of Industrial Pharmacy", 2015 |
MOHANACHANDRAN ET AL.: "International Journal of Pharmaceutical Sciences Review and Research", vol. 6, 2011, pages: 105 |
ROWE ET AL.: "Handbook of Pharmaceutical Excipients", 2009 |
RUSSO ET AL., J. PHARM. SCI., vol. 95, 2006, pages 2253 |
SHOJAEI, J., PHARM. PHARMACEUTICAL SCI, vol. 15, 1998, pages 19 |
VENGEROVICH ET AL., BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 163, 2017, pages 737 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB202019241D0 (en) | Pharmaceutical composition | |
GB201911517D0 (en) | Pharmaceutical composition | |
IL304290A (en) | Pharmaceutical composition | |
PL3908321T3 (en) | Pharmaceutical composition | |
GB202117015D0 (en) | New pharmaceutical composition | |
GB202117007D0 (en) | New pharmaceutical composition | |
GB202117005D0 (en) | New pharmaceutical composition | |
GB202018901D0 (en) | New pharmaceutical composition | |
GB202009905D0 (en) | New pharmaceutical composition | |
GB202007328D0 (en) | New pharmaceutical composition | |
GB202007306D0 (en) | New pharmaceutical composition | |
GB202208464D0 (en) | Pharmaceutical composition | |
GB202109271D0 (en) | Pharmaceutical composition | |
GB202108387D0 (en) | Pharmaceutical composition | |
GB202107518D0 (en) | Pharmaceutical composition | |
GB202105858D0 (en) | Pharmaceutical composition | |
GB202105462D0 (en) | Pharmaceutical composition | |
GB202105047D0 (en) | Pharmaceutical composition | |
GB202105049D0 (en) | Pharmaceutical composition | |
GB202104224D0 (en) | Pharmaceutical composition | |
GB202102100D0 (en) | Pharmaceutical composition | |
GB202102095D0 (en) | Pharmaceutical composition | |
GB202101638D0 (en) | Pharmaceutical composition | |
GB202101634D0 (en) | Pharmaceutical composition | |
GB202101640D0 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |